17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2022-000336-28-DE
(EUCTR)
12/12/202228/07/2022A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System AtrophyA Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: TAK-341
Product Code: TAK-341
INN or Proposed INN: Not assigned
Other descriptive name: Human IgG1 monoclonal antibody against alpha-synuclein
Takeda Development Center Americas, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
138Phase 2United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain
2NCT00750867
(ClinicalTrials.gov)
June 20089/9/2008Treatment of Multiple System Atrophy Using Intravenous ImmunoglobulinsTreatment of Multiple System Atrophy Using Intravenous ImmunoglobulinsMultiple System AtrophyDrug: intravenous immunoglobulin (IVIg)University of Massachusetts, WorcesterNULLCompleted18 YearsN/AAll9Phase 2United States